



2022 Consultant Pharmacist: Medication Management for the Older Adult -Updates in Management of Type 2 Diabetes

Dr. Allison Helmer

Recorded Webinar



PROGRAM OVERVIEW

The American Diabetes Association (ADA) releases updates to their Standards of Medical Care in Diabetes every January. Over the last few years, including 2022, the ADA has made significant changes to recommendations for treatment of type 2 diabetes, primarily due to emerging evidence expanding the role of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i). With multiple trials published each year, it can be difficult to stay up-to-date with new recommendations and approvals. The goal of this presentation is to review the evidence that led to the changes in the ADA recommendations in recent years, with a particular focus on the use of GLP-1 RA and SGLT2i in patients with diabetes as well as atherosclerotic cardiovascular disease, chronic kidney disease, and/or heart failure.

The registration fee for this program is \$25.

Following registration, participants will have access to course instructions, updates, presentations, webinar link, program evaluation, CE certificates and credits, etc. **This program is approved for 1 ACPE Contact Hours, .1 CEUs.** Once credit is awarded, transcripts will be available online within 24 hours on the learner's CPE Monitor profile at <http://nabp.pharmacy/>.

The Office of Alumni and Professional Affairs strongly encourages each participant to check their profile online within 60 days of attendance to ensure credit has been awarded properly. ACPE will not accept CE submissions after 60 days from the live seminar date.

This program is not sponsored by an external organization.

TARGET AUDIENCE

This knowledge-based program is intended for Pharmacists (ACPE)

LEARNING OBJECTIVES

- Summarize major updates to the American Diabetes Association (ADA) Standards of Medical Care in Diabetes – 2022
- Discuss data supporting the use of glucose-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) for patients with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD)
- Discuss data supporting the use of SGLT2i in patients with heart failure
- Recommend evidence-based pharmacotherapy for the management of hyperglycemia based on patient-specific factors according to the ADA Standards of Medical Care in Diabetes – 2022
- Recognize the role of finerenone in patients CKD

PROGRAM FACULTY

[Allison Helmer](#)

ACTIVITY COMPLETION REQUIREMENTS

To complete the steps for CE credit, each attendee will be required to access and review program materials located within the online course, watch the recorded webinar, take the quiz, complete the program evaluation within the online course, and claim credit within the course. Please contact hsopce@auburn.edu if you have any questions or needs related to this online CE program.

FACULTY DISCLOSURES

Programming in with AUHSOP is in any way involved, whether as sole provider or joint-providership, shall exhibit fair content balance, providing the audience with information of multiple perspectives from which to form a professional opinion. In addition, the fair balance will assure that information provided does not discuss a commercial product. Brand names of all products included in the content may be mentioned for identification purposes only. Presenters in any continuing education offering will acknowledge and disclose any affiliation with the provider and such information will be made available to the audience.

Faculty disclosures will also be included on an introductory slide during the presentation. Dr. Helmer has no actual or potential conflict of interest in relation to this program.

ACCREDITATION INFORMATION



The Auburn University Harrison School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education; credits are recognized nationwide. The Universal Activity Number for this knowledge-based program is **0001-0000-22-059-H01-P** and is intended for pharmacists. The initial release date for this live program is June 10, 2022, and the intended expiration date is June 10, 2025.

Auburn University Harrison School of Pharmacy is a Board-approved provider of continuing nursing education in Alabama by the Alabama Board of Nursing. Provider Number: ABNP1515

POST-GRADUATE EDUCATION ADVISORY COMMITTEE

Spencer Durham, Pharm.D., BCPS, BCIDP
Associate Clinical Professor, Director of Alumni & Professional Affairs

Alison Baker, Pharm.D.
Coordinator of Distributive Services, AU Employee Pharmacy

Angela Calderon, Ph.D.
Associate Professor, Drug Discovery and Development

Sarah Cogle, Pharm.D., BCCCP
Assistant Clinical Professor, Pharmacy Practice

Edward Chou, Ph.D.
Associate Professor
Department: Health Outcomes Research and Policy

Renee' Delaney, MBA
Operations Manager, COACH

Sarah Kimble, CPhT
Lead Pharmacy Technician, Auburn University Employee Pharmacy

Erika Kleppinger, Pharm.D., BCPS
Associate Clinical Professor, Pharmacy Practice

Haley Phillippe, Pharm.D., BCPS, BCGP, FASCP
Associate Clinical Professor, Pharmacy Practice

Danielle Waites, MSW
Patient Care Coordinator, Clinical Affairs and Outreach

Marian Williams, MS
Academic Programs Administrator, Faculty Affairs and Strategic Initiatives

Tanja Redd, MBA
Program Coordinator, Alumni and Professional Affairs

Brianna Foster
Program Administrator, Alumni and Professional Affairs

Members of the Post-Graduate Education Advisory Committee have completed a conflict-of-interest disclosure form and have no actual or potential conflicts of interest in relation to this program.